Caribou Biosciences, Inc. (CRBU)

Caribou Biosciences, Inc. (CRBU) Healthcare & Pipeline Overview

Caribou Biosciences is a clinical-stage biopharmaceutical firm leveraging its CRISPR-Cas9 genome editing platform to develop allogeneic cell therapies, primarily targeting hematologic malignancies and solid tumors. Their innovative approach positions them within the competitive biotechnology sector, focusing on next-generation cancer treatments.

What Is the Investment Thesis for CRBU?

Caribou Biosciences presents a notable research candidate within the biotechnology sector, driven by its innovative CRISPR-Cas9 platform and promising clinical pipeline. The company's lead candidate, CB-010, is currently in Phase 1 trials showing initial promise in treating relapsed or refractory B cell non-Hodgkin lymphoma. Successful clinical trial outcomes and potential FDA approval could significantly increase the company's value. Key value drivers include the advancement of CB-011 and CB-012 through clinical development, as well as the expansion of its CAR-NK cell therapy program, CB-020, into solid tumors. However, the company's high beta of 2.46 indicates significant volatility, and its negative profit margin of -1189.1% highlights the risks associated with clinical-stage biopharmaceutical companies. The collaboration with AbbVie provides validation and potential revenue streams, but the company's success hinges on positive clinical data and regulatory approvals.

Based on FMP financials and quantitative analysis

CRBU Key Highlights

• Market capitalization of $179.83M reflects investor sentiment and growth potential in the competitive biotechnology landscape.
• Gross margin of 82.5% indicates strong potential profitability upon commercialization of successful therapies.
• Profit margin of -1189.1% highlights the significant R&D investment typical of clinical-stage biopharmaceutical companies.
• Lead product candidate CB-010 is in Phase 1 clinical trials, representing a key milestone in the company's development pipeline.
• Collaboration with AbbVie provides validation of Caribou's technology and potential for future revenue streams.

Who Are CRBU's Competitors?

CRBU is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CRBU's Key Strengths?

• Proprietary CRISPR-Cas9 technology platform.
• Promising clinical pipeline with multiple product candidates.
• Strategic collaboration with AbbVie.
• Experienced management team.

What Are CRBU's Weaknesses?

• Clinical-stage company with no currently approved products.
• High operating expenses and negative profit margins.
• Reliance on clinical trial success for future growth.
• Intense competition in the cell and gene therapy space.

What Could Drive CRBU Stock Higher?

• Data readouts from the Phase 1 clinical trial of CB-010 in relapsed or refractory B cell non-Hodgkin lymphoma.
• Initiation of clinical trials for CB-012 in relapsed or refractory acute myeloid leukemia.
• Continued advancement of CB-011 through clinical development for relapsed or refractory multiple myeloma.
• Expansion of the collaboration with AbbVie to develop new CAR-T cell therapies.
• Presentation of preclinical data on CB-020 for solid tumors at scientific conferences.

What Are the Key Risks for CRBU?

• Financial-distress signal — its Altman Z-Score of -5.18 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or delays could negatively impact the company's stock price and future prospects.
• Regulatory hurdles and approval delays could delay the commercialization of its therapies.
• Competition from other cell and gene therapy companies could limit its market share.
• Patent challenges and intellectual property disputes could threaten its competitive advantage.
• High operating expenses and negative profit margins require continued access to capital.

What Are the Growth Opportunities for CRBU?

• Expansion of CB-010 into earlier lines of B-cell non-Hodgkin lymphoma treatment represents a significant growth opportunity. The market for lymphoma treatment is substantial, with a global market size projected to reach $15 billion by 2028. Positive Phase 1 data could support further clinical development and potential expansion into a broader patient population, providing a competitive advantage over existing therapies. Timeline: Ongoing clinical trials with potential for expanded indications within the next 3-5 years.
• Advancement of CB-011 in multiple myeloma offers a targeted approach to a challenging hematologic malignancy. The multiple myeloma market is expected to grow to $37.5 billion by 2030. Successful clinical trials and regulatory approval could establish CB-011 as a key treatment option, addressing the unmet needs of patients with relapsed or refractory disease. Timeline: Continued clinical development with potential for regulatory submission in 3-4 years.
• Development of CB-012 for acute myeloid leukemia (AML) provides an opportunity to address a high unmet need in a difficult-to-treat cancer. The AML market is projected to reach $3.5 billion by 2027. CB-012's novel anti-CD371 CAR-T cell therapy approach could offer a new treatment option for patients who have failed other therapies. Timeline: Preclinical and early clinical development with potential for later-stage trials in 2-3 years.
• Expansion into solid tumors with CB-020, an allogeneic CAR-NK cell therapy, represents a significant growth opportunity beyond hematologic malignancies. The solid tumor market is substantially larger than hematologic cancers, offering a vast potential market. Overcoming the challenges of targeting solid tumors with cell therapies could provide a significant competitive advantage. Timeline: Early-stage research and development with potential for clinical trials in 3-5 years.
• Strategic partnerships and collaborations, such as the collaboration with AbbVie, can accelerate the development and commercialization of Caribou's therapies. These partnerships provide access to resources, expertise, and funding, which can enhance the company's ability to bring its products to market. The global market for CAR-T cell therapies is expected to reach $10 billion by 2028. Timeline: Ongoing collaboration with potential for expanded partnerships in the next 1-2 years.

What Opportunities Does CRBU Have?

• Expansion of existing programs into new indications.
• Development of novel cell therapies for solid tumors.
• Strategic partnerships and collaborations.
• Potential for breakthrough therapy designations and accelerated approvals.

What Threats Does CRBU Face?

• Clinical trial failures or delays.
• Regulatory hurdles and approval delays.
• Competition from other cell and gene therapy companies.
• Patent challenges and intellectual property disputes.

What Are CRBU's Competitive Advantages?

• Proprietary CRISPR-Cas9 technology platform provides a competitive edge in gene editing.
• Strong intellectual property portfolio protects its novel cell therapies.
• Clinical data demonstrating the efficacy and safety of its therapies.
• Strategic collaborations with leading pharmaceutical companies.
• Experienced management team with expertise in cell therapy development and commercialization.

What Does CRBU Do?

Caribou Biosciences, Inc., founded in 2011 and headquartered in Berkeley, California, is a clinical-stage biopharmaceutical company dedicated to revolutionizing the treatment of cancer through genome-edited allogeneic cell therapies. The company's core technology revolves around CRISPR-Cas9, a precise and versatile gene-editing tool that allows for the development of off-the-shelf cell therapies. Caribou's lead product candidates include CB-010, an allogeneic anti-CD19 CAR-T cell therapy currently in Phase 1 clinical trials for relapsed or refractory B cell non-Hodgkin lymphoma. Additionally, CB-011, an allogeneic anti-BCMA CAR-T cell therapy, is being developed for relapsed or refractory multiple myeloma. The pipeline also includes CB-012, targeting relapsed or refractory acute myeloid leukemia, and CB-020, an allogeneic CAR-NK cell therapy for solid tumors. Caribou's strategic collaboration with AbbVie aims to further advance CAR-T cell therapy development, expanding its reach and potential impact in the field of oncology. The company's focus on allogeneic therapies addresses the limitations of autologous approaches, offering the potential for broader patient access and scalability.

What Products and Services Does CRBU Offer?

• Develops genome-edited allogeneic cell therapies.
• Focuses on treatments for hematologic malignancies and solid tumors.
• Utilizes CRISPR-Cas9 technology for precise gene editing.
• Conducts clinical trials to evaluate the safety and efficacy of its therapies.
• Collaborates with pharmaceutical companies to advance its research and development efforts.
• Aims to create off-the-shelf cell therapies for broader patient access.

How Does CRBU Make Money?

• Develops and patents novel cell therapies based on CRISPR-Cas9 technology.
• Conducts preclinical and clinical research to demonstrate the efficacy and safety of its therapies.
• Out-licenses or co-develops its therapies with pharmaceutical partners.
• Seeks regulatory approval for its therapies from agencies like the FDA.
• Commercializes approved therapies through direct sales or partnerships.

What Industry Does CRBU Operate In?

Caribou Biosciences operates within the rapidly evolving biotechnology industry, specifically in the field of cell and gene therapy. The market for cell therapies is projected to reach billions of dollars in the coming years, driven by advancements in gene editing technologies like CRISPR-Cas9. Caribou's focus on allogeneic cell therapies positions it to compete with companies developing autologous therapies, offering potential advantages in terms of scalability and cost. The competitive landscape includes companies like CRISPR Therapeutics (CRSP) and Editas Medicine (EDIT), which are also leveraging CRISPR technology for therapeutic development. The success of Caribou will depend on its ability to demonstrate clinical efficacy and navigate the complex regulatory environment.

Who Are CRBU's Key Customers?

• Patients with hematologic malignancies, such as non-Hodgkin lymphoma and multiple myeloma.
• Patients with solid tumors.
• Hospitals and cancer treatment centers.
• Pharmaceutical companies seeking to expand their oncology portfolios.

Company Profile

Caribou Biosciences, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Berkeley, US. The company is led by CEO Rachel E. Haurwitz. CRBU has traded publicly since 2021.

Caribou Biosciences, Inc. Financial Trajectory

Caribou Biosciences, Inc. (CRBU) reported $2.4M in revenue for Q1 2026, a decline of 39.2% compared to the prior quarter. The company recorded a net loss of $25.1M, with diluted EPS of $-0.26. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, CRBU averaged $-0.35 in diluted EPS.

How Caribou Biosciences, Inc. Is Valued

Caribou Biosciences, Inc. carries a market capitalization of $179.83M, placing it in the micro-cap category. Relative to its peer group, CRBU's quantitative score of 13/100 is below the peer average of 70/100.

Key Financial Metrics

Return on assets is -89.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -61.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.22 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -83.7%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 3/9Financial Health

Caribou Biosciences, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -5.18 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Caribou Biosciences, Inc. revenue of about $25.6M for fiscal 2026, with EPS near $-1.19. The estimate reflects 4 contributing analysts.

CRBU Financials

CRBU Latest News

CRBU Analyst Consensus

CRBU MoonshotScore

Common Questions About CRBU (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources